Mateus Souza Barros

Mateus Souza Barros

Auto-generated profile, based on publicly available information

Mateus Souza Barros

Diretoria de Ensino e Pesquisa, Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus, Brazil

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2021 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
NANilberto Dias de Araújo
Nilberto Dias de Araújo
FGFábio Magalhães Gama
Fábio Magalhães Gama
MBMateus de Souza Barros
Mateus de Souza Barros
TRThaís Lohana Pereira Ribeiro
Thaís Lohana Pereira Ribeiro
FAFabíola Silva Alves
Fabíola Silva Alves
ACAllyson Guimarães Costa
Allyson Guimarães Costa
Recently, cell-mediated immune response in malignant neoplasms has become the focus in immunotherapy against cancer. However, in leukemia, most studies on the cytotoxic potential of T cells have concentrated only on T cells that recognize peptide antigens (Ag) presented by polymorphic molecules of the major histocompatibility complex (MHC). This ignores the great potential of unconventional T cell populations, which include gamma-delta T cells (γδ), natural killer T cells (NKT), and mucosal-associated invariant T cells (MAIT). Collectively, these T cell populations can recognize lipid antigens, specially modified peptides and small molecule metabolites, in addition to having several other advantages, which can provide more effective applications in cancer immunotherapy. In recent years, these cell populations have been associated with a repertoire of anti- or protumor responses and play important roles in the dynamics of solid tumors and hematological malignancies, thus, encouraging the development of new investigations in the area. This review focuses on the current knowledge regarding the role of unconventional T cell populations in the antitumor immune response in leukemia and discusses why further studies on the immunotherapeutic potential of these cells are needed.

1 January 2026 in Journal of Immunology Research
Verified
Journal Article
Open access
TRThaís Lohana Chanel Pereira Ribeiro
Thaís Lohana Chanel Pereira Ribeiro
GNGlenda Menezes Nogueira
Glenda Menezes Nogueira
MSMateus Souza-Barros
Mateus Souza-Barros
JMJúlia Santos Moraes
Júlia Santos Moraes
LSLarissa Silva Santos
Larissa Silva Santos
ACAllyson Guimarães Costa
Allyson Guimarães Costa
Human leukocyte antigen G (HLA‐G) is a nonclassical major histocompatibility complex class I molecule whose increased expression has been consistently associated with unfavorable prognosis in solid tumors and has emerged as a potential immunotherapeutic target in hematological malignancies. HLA‐G exhibits limited genetic diversity and generates multiple isoforms that play a critical role in immune tolerance, being physiologically expressed in immunoprivileged tissues and aberrantly upregulated in a variety of pathological conditions, including cancer. Accumulating evidence indicates that elevated HLA‐G expression contributes to tumor immune evasion and influences clinical outcomes in patients with leukemia, lymphoma, and multiple myeloma. Genetic variability within the HLA‐G gene, particularly polymorphisms located in regulatory regions such as the 14‐base pair insertion/deletion, has been associated with cancer susceptibility, disease progression, and adverse prognosis. In hematological malignancies, specific genotypes, including the homozygous deletion variant, have been linked to increased levels of membrane‐bound and soluble HLA‐G, correlating with impaired immune surveillance and reduced survival, particularly in chronic lymphocytic leukemia. Moreover, HLA‐G expressions may be modulated by inflammatory cytokines, such as interferon‐γ, further shaping the immunosuppressive tumor microenvironment. By functioning as a nonclassical immune checkpoint, HLA‐G represents a promising target for innovative immunotherapeutic strategies, including immune checkpoint blockade combinations and chimeric antigen receptor (CAR)‐T cell approaches directed against HLA‐G‐expressing malignant cells. In this review, we summarize current knowledge regarding HLA‐G expression, genetic polymorphisms, and immunoregulatory mechanisms in hematological malignancies, highlighting their clinical and translational implications. Improved understanding of HLA‐G‐mediated immune modulation may contribute to the development of novel prognostic biomarkers and therapeutic strategies aimed at restoring effective antitumor immunity.

25 February 2026 in medRxiv
Verified
Preprint
Open access
PDF file
ISIsabelle Vasconcelos Sousa
Isabelle Vasconcelos Sousa
FMFábio Magalhães-Gama
Fábio Magalhães-Gama
BOBeatriz Silva Oliveira
Beatriz Silva Oliveira
EOEstela Yasmin Coelho Oliveira
Estela Yasmin Coelho Oliveira
JGJulia Goes Souza Ghedini
Julia Goes Souza Ghedini
ACAllyson Guimarães Costa
Allyson Guimarães Costa
Background: Acute lymphoblastic leukemia is the most common childhood malignancy; however, survival remains highly heterogeneous across regions, particularly in low- and middle-income settings. In geographically vulnerable areas such as the Brazilian Amazon, structural barriers related to health system organization, centralization of specialized services, and continuity of care may substantially influence treatment trajectories and mortality. This study aimed to examine health system and epidemiological determinants of mortality among patients with acute lymphoblastic leukemia in Amazonas, Brazil. Methods: This retrospective cohort study included 393 patients diagnosed with acute lymphoblastic leukemia between 2016 and 2021 at the state referral center for hematologic diseases in Amazonas, Brazil. Sociodemographic, clinical, laboratory, and health system–related variables were analyzed. Multivariate logistic regression models were used to identify factors associated with mortality. Spatial analyses described the geographic distribution of cases, and overall survival was evaluated using Kaplan-Meier curves. Results: The cohort was predominantly pediatric, with a substantial proportion of adolescents and young adults. Most patients presented with high-risk clinical and laboratory features at diagnosis. Mortality occurred in 48.5% of patients and was strongly associated with age at diagnosis, with higher odds of death among adolescents, young adults, and individuals aged 51–60 years. Geographic concentration of specialized services and treatment-related trajectories were closely linked to survival patterns. Conclusion: Mortality from acute lymphoblastic leukemia in the Brazilian Amazon remains high and is primarily influenced by age-related vulnerability and health system factors rather than baseline sociodemographic characteristics. These findings underscore persistent regional inequalities in access to specialized care and highlight the need for health system strengthening to improve cancer survival in geographically vulnerable settings.